Compare · Research-Use-Only
BPC-157 vs GHK-Cu
BPC-157 and GHK-Cu are the two most-cited research peptides in tissue and skin recovery models. They work through different mechanisms — BPC-157 modulates growth factor pathways across multiple tissue types; GHK-Cu acts as a copper chaperone influencing collagen synthesis and gene expression.
BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a conserved sequence within the human gastric juice protein BPC. Its remarkable stability in gastric acid, plasma, and tissue environments (hence 'stable gastric pentadecapeptide') sets it apart from most endogenous peptides. While the precise receptor has not been definitively identified, multiple mechanistic pathways have been proposed and characterized in preclinical models. BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) and promotes angiogenesis, which may underlie its wound-healing effects in tendon, ligament, and muscle tissue. It modulates nitric oxide (NO) production through interactions with both constitutive (eNOS, nNOS) and inducible (iNOS) nitric oxide synthase isoforms — with context-dependent effects that help restore vascular homeostasis. BPC-157 activates focal adhesion kinase (FAK) and paxillin — proteins critical for cell migration, adhesion, and survival — which may explain its promotion of fibroblast and keratinocyte migration in wound models. It also interacts with the GABA-B receptor system, and preclinical data suggest modulation of dopaminergic and serotonergic pathways. In gastrointestinal research, BPC-157 protects gastric mucosa by suppressing NF-κB, reducing oxidative stress, and maintaining mucosal integrity. It is notable that BPC-157 is active at very low doses (nanogram range) in most preclinical models. All mechanistic and efficacy data are currently from preclinical studies; no completed human clinical trials exist.
GHK-Cu
GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring copper-binding tripeptide first isolated from human plasma albumin by Pickart and Thaler in 1973. It is present at concentrations of ~200 ng/mL in plasma of young adults, declining substantially with age. The peptide coordinates Cu(II) through the histidine imidazole nitrogen and N-terminal amine in a square planar complex. This copper chelation is central to GHK-Cu's biological activity: the copper-peptide complex acts as a cellular copper chaperone, facilitating delivery to copper-dependent enzymes including lysyl oxidase (collagen cross-linking), superoxide dismutase (SOD1), and cytochrome c oxidase. At the cellular level, GHK-Cu activates multiple signaling pathways simultaneously. It upregulates collagen types I, III, and VI synthesis in dermal fibroblasts, stimulates production of glycosaminoglycans and proteoglycans, and promotes fibronectin and decorin expression — all components of extracellular matrix remodeling. It modulates matrix metalloproteinase (MMP) activity bidirectionally: increasing MMP-2 and MMP-9 to clear damaged matrix while also upregulating TIMP-1 and TIMP-2 to control remodeling. Gene expression analysis (Connectivity Map) shows GHK can modulate expression of over 4,000 genes, including pathways involved in inflammation (NF-κB suppression), oxidative stress (Nrf2 activation), and DNA repair. In wound healing models, GHK-Cu stimulates angiogenesis via VEGF upregulation and accelerates keratinocyte migration.
Other research peptide comparisons
Both compounds in stock at Veridian. 99%+ HPLC purity, same-day US shipping.
Browse all research peptides →